RIGL - Rigel Pharmaceuticals Inc Stock Price, Fair Value and News

1.09USD-0.01 (-0.91%)Market Closed

Market Summary

USD1.09-0.01

Market Closed

-0.91%

RIGL Stock Price

View Fullscreen

RIGL RSI Chart

RIGL Valuation

Market Cap

191.2M

Price/Earnings (Trailing)

-7.62

Price/Sales (Trailing)

1.64

EV/EBITDA

-9.33

Price/Free Cashflow

-33.29

RIGL Price/Sales (Trailing)

RIGL Profitability

EBT Margin

-21.47%

Return on Equity

87.6%

Return on Assets

-21.4%

Free Cashflow Yield

-3%

RIGL Fundamentals

RIGL Revenue

Revenue (TTM)

116.9M

Rev. Growth (Yr)

-30.2%

Rev. Growth (Qtr)

27.22%

RIGL Earnings

Earnings (TTM)

-25.1M

Earnings Growth (Yr)

-47.39%

Earnings Growth (Qtr)

112.95%

Breaking Down RIGL Revenue

Last 7 days

3.8%

Last 30 days

-23.2%

Last 90 days

-15.5%

Trailing 12 Months

-4.8%

How does RIGL drawdown profile look like?

RIGL Financial Health

Current Ratio

1.86

RIGL Investor Care

Shares Dilution (1Y)

0.99%

Diluted EPS (TTM)

-0.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	129.6M	126.6M	132.4M	116.9M
2022	85.0M	88.5M	89.4M	120.2M
2021	133.9M	144.1M	147.3M	149.2M
2020	102.4M	108.0M	105.6M	108.6M
2019	57.1M	65.8M	81.7M	59.3M
2018	0	2.7M	7.6M	44.5M
2017	18.9M	10.3M	7.5M	4.5M
2016	31.7M	35.2M	25.9M	20.4M
2015	16.2M	21.4M	28.6M	28.9M
2014	0	0	0	15.4M
2013	0	2.9M	1.4M	7.2M
2012	5.7M	6.6M	2.3M	2.3M
2011	0	84.9M	44.8M	4.8M
2010	0	0	0	125.0M
2009	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Rigel Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 05, 2024	santos david a	sold	-10,166	1.14	-8,918	evp, chief commercial officer
Feb 05, 2024	schorno dean l	sold	-8,010	1.14	-7,027	evp & chief financial officer
Feb 05, 2024	rodriguez raul r	sold	-34,821	1.14	-30,545	ceo, president
Feb 02, 2024	santos david a	sold	-6,329	1.13	-5,601	evp, chief commercial officer
Feb 02, 2024	schorno dean l	sold	-6,326	1.1296	-5,601	evp & chief financial officer
Feb 02, 2024	rodriguez raul r	sold	-25,261	1.1303	-22,349	ceo, president
Jan 23, 2024	santos david a	acquired	-	-	209,000	evp, chief commercial officer
Jan 23, 2024	furey raymond j.	acquired	-	-	209,000	evp, gc, cco & corp sec
Jan 23, 2024	schorno dean l	acquired	-	-	209,000	evp & chief financial officer
Jan 23, 2024	rodriguez raul r	acquired	-	-	400,000	ceo, president

Which funds bought or sold RIGL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	3,000	3,000	-%
Apr 25, 2024	Allworth Financial LP	unchanged	-	51.00	2,506	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-7.41	-45,083	775,544	-%
Apr 24, 2024	Assenagon Asset Management S.A.	unchanged	-	59,742	2,947,270	0.01%
Apr 23, 2024	LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA	unchanged	-	-1.00	31.00	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-74.04	-24,000	9,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	34,308	134,450	-%
Apr 19, 2024	Cutler Group LLC / CA	sold off	-100	-1,000	-	-%
Apr 18, 2024	McGlone Suttner Wealth Management, Inc.	sold off	-	-	-	-%
Apr 18, 2024	Hexagon Capital Partners LLC	unchanged	-	1.00	33.00	-%

Are Funds Buying or Selling RIGL?

Are funds buying RIGL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RIGL

No. of Funds

Unveiling Rigel Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.81%	17,100,000	SC 13G/A
Feb 13, 2024	vanguard group inc	5.13%	8,953,217	SC 13G/A
Feb 09, 2024	morgan stanley	8.3%	14,490,600	SC 13G
Feb 05, 2024	goldman sachs group inc	0.1%	255,676	SC 13G/A
Feb 02, 2024	soleus capital master fund, l.p.	5.4%	9,442,579	SC 13G/A
Jan 25, 2024	blackrock inc.	8.7%	15,198,077	SC 13G/A
Jun 12, 2023	fmr llc	-	0	SC 13G/A
Feb 22, 2023	soleus capital master fund, l.p.	5.3%	9,223,015	SC 13G
Feb 14, 2023	armistice capital, llc	9.81%	16,956,000	SC 13G
Feb 14, 2023	goldman sachs group inc	5.4%	9,370,063	SC 13G

Recent SEC filings of Rigel Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 12, 2024	8-K	Current Report
Apr 10, 2024	ARS	ARS
Apr 10, 2024	DEF 14A	DEF 14A
Apr 10, 2024	DEFA14A	DEFA14A
Mar 29, 2024	3	Insider Trading
Mar 29, 2024	4	Insider Trading
Mar 29, 2024	PRE 14A	PRE 14A
Mar 05, 2024	10-K	Annual Report
Mar 05, 2024	8-K	Current Report
Mar 01, 2024	4	Insider Trading

Peers (Alternatives to Rigel Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-1.15%	-18.78%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-5.46%	-27.26%	-41	9.87	76.23%	61.08%
BMRN	15.3B	2.4B	-6.36%	-11.66%	91.05	6.31	15.42%	18.43%
INCY	11.6B	3.7B	-9.50%	-30.40%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.85%	-43.46%	-10.93	14.57	425.83%	18.94%
BBIO	4.4B	-	-18.25%	70.26%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-6.76%	2.03%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.32%	-19.69%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-21.52%	-38.49%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-6.79%	-8.36%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.14%	-47.54%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-7.41%	335.24%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.26%	4.12%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	47.83%	55.96%	-0.22	2.14	-13.45%	66.37%

Rigel Pharmaceuticals Inc News

Latest updates

Rigel Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	27.2%	35,792,000	28,134,000	26,886,000	26,070,000	51,278,000	22,410,000	29,819,000	16,735,000	20,409,000	21,543,000	26,266,000	81,018,000	18,450,000	18,389,000	16,021,000	55,761,000	15,400,000	20,857,000	10,407,000	12,624,000	37,857,000
Costs and Expenses	3.8%	33,826,000	32,599,000	32,153,000	38,795,000	49,199,000	40,813,000	42,784,000	42,996,000	41,827,000	41,328,000	39,314,000	39,263,000	37,277,000	32,170,000	33,413,000	34,734,000	32,737,000	32,894,000	31,746,000	31,002,000	35,325,000
S&GA Expenses	8.0%	26,850,000	24,856,000	26,306,000	27,729,000	32,172,000	25,897,000	26,981,000	27,401,000	24,515,000	22,877,000	22,378,000	22,121,000	21,818,000	17,430,000	18,920,000	18,430,000	18,312,000	18,121,000	18,209,000	19,946,000	21,370,000
EBITDA Margin	62.5%	-0.15	-0.39	-0.41	-0.41	-0.45	-0.87	-0.89	-0.93	-0.08	-0.06	-0.02	-0.05	-	-	-	-	-	-	-	-	-
Interest Expenses	0.4%	1,907,000	1,899,000	1,862,000	1,204,000	1,107,000	826,000	569,000	1,205,000	1,299,000	1,317,000	1,759,000	485,000	429,000	429,000	353,000	142,000	327,000	8,000	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-100,000	-100,000	-1,000,000	1,800,000	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	1,401,000	-19,037,000	-13,492,000	-27,445,000	-22,701,000	-21,088,000	-14,791,000	41,271,000	-19,237,000	-14,174,000	-17,576,000	21,243,000	-	-	-	-	-
EBT Margin	51.5%	-0.21	-0.44	-0.46	-0.45	-0.49	-0.93	-0.96	-1.01	-0.12	-0.09	-0.05	-0.07	-	-	-	-	-	-	-	-	-
Net Income	112.9%	737,000	-5,692,000	-6,600,000	-13,536,000	1,401,000	-19,037,000	-13,492,000	-27,445,000	-22,641,000	-20,952,000	-13,821,000	39,500,000	-19,237,000	-14,174,000	-17,576,000	21,243,000	-17,200,000	-11,490,000	-20,606,000	-17,598,000	3,228,000
Net Income Margin	-16.3%	-0.21	-0.18	-0.30	-0.34	-0.49	-0.92	-0.96	-1.00	-0.12	-0.10	-0.05	-0.09	-	-	-	-	-	-	-	-	-
Free Cashflow	-359.2%	-6,240,000	-1,359,000	5,857,000	-4,147,000	-21,982,000	-13,490,000	-12,875,000	-25,861,000	-19,065,000	-10,467,000	54,809,000	-20,026,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	1.6%	117	115	117	124	134	116	128	149	167	187	202	216	110	123	138	143	148	156	156	173	139
Current Assets	4.5%	99.00	95.00	101	107	116	110	121	139	154	171	184	197	89.00	100	113	116	119	126	125	139	137
Cash Equivalents	-27.8%	33.00	45.00	49.00	40.00	24.00	30.00	27.00	25.00	19.00	30.00	85.00	20.00	30.00	37.00	36.00	45.00	23.00	39.00	44.00	75.00	76.00
Inventory	-9.7%	6.00	6.00	11.00	11.00	9.00	7.00	6.00	7.00	7.00	7.00	7.00	7.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00
Net PPE	-13.2%	0.00	0.00	0.00	0.00	1.00	2.00	2.00	2.00	2.00	3.00	3.00	2.00	3.00	3.00	2.00	3.00	2.00	2.00	2.00	2.00	1.00
Liabilities	-0.9%	146	147	145	148	148	-	-	-	137	-	-	-	-	-	-	-	-	-	-	-	-
Current Liabilities	10.3%	53.00	48.00	44.00	46.00	65.00	47.00	55.00	59.00	64.00	59.00	60.00	52.00	41.00	34.00	35.00	31.00	58.00	31.00	28.00	26.00	28.00
Shareholder's Equity	-Infinity%	-28.64	-	-	-	-13.62	-	-	7.00	30.00	50.00	68.00	78.00	34.00	51.00	63.00	78.00	54.00	69.00	78.00	95.00	110
Retained Earnings	0.1%	-1,407	-1,408	-1,402	-1,395	-1,382	-1,383	-1,364	-1,351	-1,323	-1,301	-1,280	-1,266	-1,305	-1,286	-1,272	-1,254	-1,276	-1,259	-1,247	-1,226	-1,209
Additional Paid-In Capital	0.2%	1,379	1,376	1,374	1,372	1,369	1,364	1,361	1,358	1,354	1,351	1,348	1,345	1,340	1,338	1,336	1,333	1,330	1,328	1,326	1,322	1,319
Shares Outstanding	0.3%	175	174	174	174	173	173	172	172	170	171	170	170	-	-	-	-	-	-	-	-	-
Float	-	-	-	223	-	-	-	194	-	-	-	740	-	-	-	309	-	-	-	437	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-359.2%	-6,240	-1,359	5,930	-4,074	-21,909	-13,301	-12,911	-25,637	-19,086	-10,297	55,216	-19,955	-15,572	-19,482	-14,038	-3,093	-9,649	-14,641	-16,651	-569	11,644
Share Based Compensation	-0.5%	1,933	1,943	2,172	2,758	4,080	2,707	2,391	3,207	2,339	2,202	2,306	2,639	1,632	1,884	1,757	2,024	1,411	2,098	2,653	2,953	2,057
Cashflow From Investing	-487.5%	-6,874	-1,170	2,970	777	18,598	10,455	21,095	22,629	6,488	-44,397	-49,659	7,532	8,711	19,528	-5,234	24,461	-7,617	-294	-14,672	-1,073	2,093
Cashflow From Financing	155.9%	486	-869	-373	19,123	-2,096	5,511	-5,662	8,797	1,085	274	59,219	2,097	667	52.00	10,516	1,336	694	9,799	856	16.00	1,099

RIGL Income Statement

2023-12-31

STATEMENTS OF OPERATIONS - USD ($) shares in Thousands	12 Months Ended
STATEMENTS OF OPERATIONS - USD ($) shares in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Total revenues	$ 116,882,000	$ 120,242,000	$ 149,236,000
Costs and expenses:
Cost of product sales	7,110,000	1,749,000	1,083,000
Research and development	24,522,000	60,272,000	65,237,000
Selling, general and administrative	105,741,000	112,451,000	91,891,000
Restructuring charges		1,320,000	3,521,000
Total costs and expenses	137,373,000	175,792,000	161,732,000
Loss from operations	(20,491,000)	(55,550,000)	(12,496,000)
Interest income	2,272,000	684,000	47,000
Interest expense	(6,872,000)	(3,707,000)	(4,860,000)
Loss before income taxes	(25,091,000)	(58,573,000)	(17,309,000)
Provision for income taxes			605,000
Net loss	$ (25,091,000)	$ (58,573,000)	$ (17,914,000)
Net loss per share, basic (in dollars per share)	$ (0.14)	$ (0.34)	$ (0.11)
Net loss per share, diluted (in dollars per share)	$ (0.14)	$ (0.34)	$ (0.11)
Weighted average shares used in computing net loss per share, basic (in shares)	174,017	172,406	170,492
Weighted average shares used in computing net loss per share, diluted (in shares)	174,017	172,406	170,492
Product sales, net
Total revenues	$ 104,294,000	$ 76,718,000	$ 63,010,000
Revenues from collaborations
Total revenues	11,488,000	39,024,000	75,726,000
Government contracts
Total revenues	$ 1,100,000	$ 4,500,000	$ 10,500,000

RIGL Balance Sheet

2023-12-31

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 32,786	$ 24,459
Short-term investments	24,147	33,747
Accounts receivable, net	30,550	40,320
Inventories	5,522	9,118
Prepaid and other current assets	6,261	8,259
Total current assets	99,266	115,903
Property and equipment, net	165	857
Intangible asset, net	13,878	14,949
Operating lease right-of-use asset	861	1,930
Other assets	3,055	640
Total assets	117,225	134,279
Current liabilities:
Accounts payable	7,142	22,508
Accrued compensation	8,676	8,866
Accrued research and development	3,513	7,708
Revenue reserves and refund liability	15,684	12,145
Other accrued liabilities	5,334	6,485
Lease liabilities, current portion	692	1,133
Deferred revenue	1,355	1,369
Loans payable, net, current portion	7,229
Other long-term liabilities, current portion	3,642	4,997
Total current liabilities	53,267	65,211
Long-term portion of lease liabilities	285	972
Long-term portion of loans payable, net of discount	52,373	39,448
Other long-term liabilities	39,944	42,264
Total liabilities	145,869	147,895
Commitments
Stockholders' deficit:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; none issued and outstanding as of December 31, 2023 and 2022
Common stock, $0.001 par value; 400,000,000 shares authorized; 174,825,610 and 173,398,645 shares issued and outstanding as of December 31, 2023 and 2022, respectively	175	174
Additional paid-in capital	1,378,723	1,368,822
Accumulated other comprehensive income (loss)	8	(153)
Accumulated deficit	(1,407,550)	(1,382,459)
Total stockholders' deficit	(28,644)	(13,616)
Total liabilities and stockholders' deficit	$ 117,225	$ 134,279

About Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. It also develops Fostamatinib that has conducted phase III clinical trials for the treatment of warm autoimmune hemolytic anemia; has completed FOCUS phase III clinical trial for the treatment of hospitalized high-risk patients COVID-19; and that is in phase II/III clinical trials for the treatment of COVID-19 in hospitalized patients. In addition, the company's other clinical programs include interleukin receptor-associated kinase inhibitor program and a receptor-interacting serine/threonine-protein kinase inhibitor program in clinical development with partner Eli Lilly and Company. Further, it has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

CEO	Mr. Raul R. Rodriguez
WEBSITE	rigel.com
INDUSTRY	Biotechnology
EMPLOYEES	155

Rigel Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Rigel Pharmaceuticals Inc? What does RIGL stand for in stocks?

RIGL is the stock ticker symbol of Rigel Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Rigel Pharmaceuticals Inc (RIGL)?

As of Thu Apr 25 2024, market cap of Rigel Pharmaceuticals Inc is 192.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RIGL stock?

You can check RIGL's fair value in chart for subscribers.

What is the fair value of RIGL stock?

You can check RIGL's fair value in chart for subscribers. The fair value of Rigel Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Rigel Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RIGL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Rigel Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether RIGL is over valued or under valued. Whether Rigel Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Rigel Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RIGL.

What is Rigel Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, RIGL's PE ratio (Price to Earnings) is -7.69 and Price to Sales (PS) ratio is 1.65. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RIGL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Rigel Pharmaceuticals Inc's stock?

In the past 10 years, Rigel Pharmaceuticals Inc has provided -0.1 (multiply by 100 for percentage) rate of return.